Merck KGaA Forecasts Earnings, Sales Growth
Merck, Keytruda and patent
What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...
The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
A sinus infection, known as sinusitis, is one of the most common medical conditions. But in some cases, it can come with dangerous complications.
On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback